Sialic Acid Binding Ig-like Lectin 2
"Sialic Acid Binding Ig-like Lectin 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
| Descriptor ID |
D051918
|
| MeSH Number(s) |
D12.776.395.550.200.810 D12.776.503.921.200 D12.776.543.550.200.810 D23.050.301.350.720
|
| Concept/Terms |
Sialic Acid Binding Ig-like Lectin 2- Sialic Acid Binding Ig-like Lectin 2
- Sialic Acid Binding Ig like Lectin 2
- CD22 Glycoprotein
- Glycoprotein, CD22
- Siglec-2
- Antigens, CD22
- CD22 Antigens
- B-Lymphocyte Cell Adhesion Molecule
- B Lymphocyte Cell Adhesion Molecule
- CD22 Antigen
- Antigen, CD22
|
Below are MeSH descriptors whose meaning is more general than "Sialic Acid Binding Ig-like Lectin 2".
Below are MeSH descriptors whose meaning is more specific than "Sialic Acid Binding Ig-like Lectin 2".
This graph shows the total number of publications written about "Sialic Acid Binding Ig-like Lectin 2" by people in this website by year, and whether "Sialic Acid Binding Ig-like Lectin 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sialic Acid Binding Ig-like Lectin 2" by people in Profiles.
-
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 07 04; 144(1):61-73.
-
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
-
Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults. Oncology (Williston Park). 2019 07 16; 33(7).
-
Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol. 2018 10 01; 4(10):1413-1420.
-
Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018 05 15; 124(10):2151-2160.
-
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242.
-
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444.
-
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53.
-
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol. 2016; 9(4):329-34.
-
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther. 2015 Apr; 15(4):601-11.